Cronos Group Inc. Q2 FY2026 earnings call

Operational Progress on Integrated Facilities

• The GroCo cultivation and manufacturing facility is fully online and integrated, with management noting the ramp-up is progressing very well. The team has gained full control over production scheduling to process increased output from the expanded facility.
• Manufacturing operations at the Stainer facility in Israel are continuing to improve as processes are refined.

Product and Genetic Development

• The company's multi-year genetic breeding program delivers incremental annual improvements, and management identifies genetic advances as the largest potential source of future efficiency gains, even above facility expansion.
• The company holds leading market positions in edibles, and has built growing strength in pre-rolls and vapes, with expanded supply from GroCo supporting these product lines.

Market Positioning

• Canadian consumer demand has remained resilient for the company's portfolio. The company focuses on delivering strong value propositions across product categories, and has observed some category switching into cannabis from higher-cost alcohol products.

No segment-level financial performance data (absolute values or revenue contribution percentages) was disclosed in the provided transcript.

No formal forward-looking financial or operational guidance, including upward/downward revisions to prior guidance, was provided in the provided transcript.

• The company is currently facing a second anti-dumping investigation related to its Israel market operations. Management states the investigation is unmerited, and the company is confident it will prevail again as it did in a prior proceeding.
• Low stock liquidity is an ongoing challenge for NASDAQ-listed Canadian cannabis licensed producers, including this firm.

Q: Were the quarter's results better than internal expectations, and what key factors drove the strong performance? / A: Management confirmed the team is extremely pleased with the results, which outperformed their typically conservative internal outlook. Favorable growing season weather boosted yields, and multi-year strategic investments are now delivering results, with improving operations at both GroCo in Canada and Stainer in Israel. Most core markets are moving in a positive direction.

Q: How is the GroCo integration progressing, and how does expanded supply support market share gains and future margin performance? / A: GroCo is fully online and fully integrated for processing, with scheduling now fully under control. Expanded supply has supported mixed market share gains across product categories, alongside strength in pre-rolls and vapes and a maintained leading position in edibles. The largest future efficiency gains are expected from the ongoing genetic breeding program rather than facility buildout, with incremental improvements rolling out annually.

Q: What is the current structure of your Israel supply chain, and how would you address potential import restrictions? / A: The company has domestic cultivation in Israel, purchases product from third parties (both domestic and international, including GroCo Canada), and conducts all packaging and manufacturing in-region for its branded Israel sales. The company has proactively increased supply specifically for the Israel market and is confident it will prevail in the ongoing anti-dumping investigation, which management argues is unmerited.

Q: If U.S. cannabis is rescheduled but retains the current state-siloed system with no interstate commerce, would the company still enter the U.S. market? / A: The company would still enter, but would focus on borderless, IP-based product offerings rather than building large-scale domestic cultivation infrastructure. Entry would focus on leveraging the company's genetics, edibles, vapes, and pre-rolls, rather than full in-state production. Management expects interstate commerce will eventually be allowed long-term, so state-by-state infrastructure buildout is not strategic at this stage.